drugset / Trial / NCT02026362
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
Phase 1/2
Suspended
100 enrolled
HRYZ Biotech Co.
Beijing 302 Hospital · collabFujian Cancer Hospital · collabNanfang Hospital, Southern Medical University · collabSun Yat-sen University · collabThird Affiliated Hospital, Sun Yat-Sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.
Timeline
- Start
- 2013-07
- Primary completion
- 2017-07
- Completion
- 2019-12
Outcome
Outcome not reported
Stopped: “Interim analysis”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Multiple Antigens Specific Cellular Therapy | Cell therapy | — | — |